Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.38 |
| ▸ | RAF1 | P04049 | 4/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610234 | 0.88 | AR (0.37) | ARRAF1MAP2K1RAB9ADRD1 | |
| SCHEMBL21610266 | 0.88 | AR (0.38) | ARRAB9ASGK1CYP3A4CYP2C19 | |
| SCHEMBL21610206 | 0.87 | AR (0.43) | ARRAB9ADRD1CYP3A4CYP2C19 | |
| SCHEMBL21580674 | 0.86 | AR (0.40) | ARPLA2G7DRD1CYP3A4CYP2C19 | |
| SCHEMBL24350553 | 0.85 | AR (0.38) | ARRAF1MAP2K1PLA2G7DRD1 | |
| SCHEMBL21610141 | 0.85 | AR (0.40) | ARRAF1MAP2K1PLA2G7DRD1 | |
| SCHEMBL21610220 | 0.83 | ALDH1A1 (0.41) | ARPLA2G7DRD1CYP3A4CYP2C19 | |
| SCHEMBL31690567 | 0.83 | ALDH1A1 (0.41) | ARPLA2G7DRD1CYP3A4CYP2C19 | |
| SCHEMBL21610211 | 0.81 | AR (0.38) | ARDRD1BACE1BACE2CYP3A4 | |
| SCHEMBL21580616 | 0.81 | AR (0.50) | ARRAB9APLA2G7DRD1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947365-B1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-11-12 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3947365-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | Bionomics Limited (AU) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | AR 4592/4885RAF1 2349/4885MAP2K1 3186/4885 |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | SCN3A, KCND3, GRIN3A | AR 2466/4885RAF1 1163/4885MAP2K1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.